Abstract:The oncoprotein MYC has the dual capacity to drive cell cycle progression or induce apoptosis, depending on the cellular context. BAG1 was previously identified as a transcriptional target of MYC that functions as a critical determinant of this cell fate decision. The BAG1 protein is expressed as multiple isoforms, each having an array of distinct biochemical functions; however, the specific effector function of BAG1 that directs MYC-dependent cell survival has not been defined.In our studies the human osteosarcoma line U2OS expressing a conditional MYC-ER allele was used to induce oncogenic levels of MYC. We interrogated MYC-driven survival processes by modifying BAG1 protein expression. The function of the separate BAG1 isoforms was investigated by depleting cells of endogenous BAG1 and reintroducing the distinct isoforms. Flow cytometry and immunoblot assays were performed to analyze the effect of specific BAG1 isoforms on MYC-dependent apoptosis. These experiments were repeated to determine the role of the HSP70 chaperone complex in BAG1 survival processes. Finally, a proteomic approach was used to identify a set of specific pro-survival proteins controlled by the HSP70/BAG1 complex.Loss of BAG1 resulted in robust MYC-induced apoptosis. Expression of the larger isoforms of BAG1, BAG1L and BAG1M, were insufficient to rescue survival in cells with oncogenic levels of MYC. Alternatively, reintroduction of BAG1S significantly reduced the level of apoptosis. Manipulation of the BAG1S interaction with HSP70 revealed that BAG1S provides its pro-survival function by serving as a cofactor for the HSP70 chaperone complex. Via a proteomic approach we identified and classified a set of pro-survival proteins controlled by this HSP70/BAG1 chaperone complex that contribute to the BAG1 anti-apoptotic phenotype.The small isoform of BAG1, BAG1S, in cooperation with the HSP70 chaperone complex, selectively mediates cell survival in MYC overexpressing tumor cells. We identified a set of specific pro-survival clients controlled by the HSP70/BAG1S chaperone complex. These clients define new nodes that could be therapeutically targeted to disrupt the survival of tumor cells driven by MYC activation. With MYC overexpression occurring in most human cancers, this introduces new strategies for cancer treatment.

BAG2 is a target of the c-Myc gene and is involved in cellular senescence via the p21(CIP1) pathway.

Interaction between the BAG1S isoform and HSP70 mediates the stability of anti-apoptotic proteins and the survival of osteosarcoma cells expressing oncogenic MYC

DSG2 and C-Myc Interact to Regulate the Expression of ADAM17 and Promote the Development of Cervical Cancer

Molecular Insights of c-Myc in Cellular Senescence

TBX2 controls a proproliferative gene expression program in melanoma

C-Myc-induced Chemosensitization is Mediated by Suppression of Cyclin D1 Expression and Nuclear Factor-Kappa B Activity in Pancreatic Cancer Cells.

BAG2 promotes tumorigenesis through enhancing mutant p53 protein levels and function

BAG3: a New Therapeutic Target of Human Cancers?

Cellular senescence and aging: the role of B-MYB

Suppression of TCAB1 expression induced cellular senescence by lessening proteasomal degradation of p21 in cancer cells

Comparative analysis of BAG1 and BAG2: Insights into their structures, functions and implications in disease pathogenesis

Genome-wide binding analysis unveils critical implication of B-Myb-mediated transactivation in cancers

B-MYB Delays Cell Aging by Repressing P16 INK4α Transcription

PP2A-B56α controls oncogene-induced senescence in normal and tumor human melanocytic cells

Bcl-2-associated athanogene 3(BAG3) is associated with tumor cell proliferation, migration, invasion and chemoresistance in colorectal cancer

Inhibitory Effect of Bcl-2 on P53-Mediated Transactivation Following Genotoxic Stress

Senescence-related gene c-Myc affects bladder cancer cell senescence by interacting with HSP90B1 to regulate cisplatin sensitivity

Mel-18, a Polycomb Group Protein, Regulates Cell Proliferation and Senescence Via Transcriptional Repression of Bmi-1 and C-Myc Oncoproteins.

Cancer-testis antigen MAGE-C2 binds Rbx1 and inhibits ubiquitin ligase-mediated turnover of cyclin E.

BTG2 acts as an inducer of muscle stem cell senescence

Global Mapping Of C-Myc Binding Sites And Target Gene Networks In Human B Cells